• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Cyclosporine Ophthalmic Solution Safe, Accessible in Uncontrollable Dry Eye

News
Video

Michelle Hessen, OD, discusses how cyclosporine ophthalmic solution 0.09% is safe to use in patients with dry eye, as well as where future research should turn.

Michelle Hessen, OD, assistant professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins Medicine, spoke about the future direction of study when focusing on cyclosporine ophthalmic solution 0.09% (Cequa; Sun Pharmaceutical) and how it can help those with uncontrollable dry eye.

This transcript has been lightly edited for clarity; captions were auto-generated.

Transcript

Should cyclosporine ophthalmic solution, 0.09%, be used indefinitely?

That's a great question. In the treatment of dry eye, we not only want to improve patient symptoms, but as well as the signs of their dry eye, meaning the corneal fluorescein staining, as well as lissamine green staining. As long as these patients are continuing to improve and are comfortable, I would probably continue them on the Cequa, unless otherwise indicated as this is a very safe drug, and most patients tolerate it very well, despite some mild installation irritation,

How accessible is this treatment for patients?

At this time, I feel like Cequa accessibility has improved greatly over the last probably couple of years, such that it is covered by most commercial insurances, as well as some Medicare plans and Medicaid.

What should research into uncontrollable dry eye focus on in the future?

I think one area that that should still be studied is that [in] patients with severe corneal and conjunctival staining, if an increased dose of Cequa would give any additional benefit as compared to the twice-daily dosing.

Related Videos
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre
Jill Feldman, patient, cofounder and president, EGFR Resisters
Reynold Panettieri, Jr, MD
Danny Rischin, MD, medical oncologist, clinician researcher, Peter McCallum Cancer Centre
James Chalmers, MD
Ibrahim Aldoss, MD, associate professor, City of Hope
James Chalmers, MD
Vincent Picozzi, MD, medical oncologist and director of the pancreaticobiliary program, Virginia Mason
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.